DTCFF (Defence Therapeutics) YoY EBITDA Growth: -125.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DTCFF Defence Therapeutics Inc DTCFF
21 GF Score
Price $0.36
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics YoY EBITDA Growth?

Defence Therapeutics DTCFF +3.75% 21 YoY EBITDA Growth is -125.00% as of Mar. 2026. GuruFocus rates DTCFF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Defence Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -125.00%.

Defence Therapeutics's EBITDA per Share for the three months ended in Mar. 2026 was $-0.04.

Defence Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Defence Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics YoY EBITDA Growth Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial -528.57 -80.68 21.38 -66.40 77.88

Defence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.00 50.00 0.00 -80.00 -125.00
DTCFF
21GF Score
Defence Therapeutics Inc DTCFF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Defence Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Defence Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.046--0.208)/ | -0.208 |
=77.88 %

Defence Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.036--0.016)/ | -0.016 |
=-125.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -125.00% mean?
Defence Therapeutics (DTCFF) has a YoY EBITDA Growth of -125.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Defence Therapeutics and its competitors.
Is Defence Therapeutics' YoY EBITDA Growth too high?
Defence Therapeutics' current YoY EBITDA Growth is -125.00%. Overall, Defence Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' YoY EBITDA Growth compare to VRTX and REGN?
Defence Therapeutics' YoY EBITDA Growth of -125.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Defence Therapeutics and its competitors. Defence Therapeutics's current YoY EBITDA Growth is -125.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current YoY EBITDA Growth of -125.00%. The current YoY EBITDA Growth is -125.00%. Defence Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current YoY EBITDA Growth is -125.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Other Exchanges DTC:GermanyDTC:Canada
Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
21GF Score

Get the complete analysis for DTCFF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.36
Price